Legal & General Group
RAPP

Legal & General Group’s Rapport Therapeutics RAPP Stock Holding History

Legal & General Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$940K Buy
22,555
+5,401
+31% +$199K ﹤0.01% 2225
2026
Q1 		$537K Sell
17,154
-5,230
-23% -$147K ﹤0.01% 2338
2025
Q4 		$679K Sell
22,384
-11,509
-34% -$319K ﹤0.01% 2333
2025
Q3 		$1.01M Buy
33,893
+32,240
+1,950% +$575K ﹤0.01% 2237
2025
Q2 		$18.8K Sell
1,653
-8,643
-84% -$91.7K ﹤0.01% 3032
2025
Q1 		$103K Buy
10,296
+773
+8% +$10K ﹤0.01% 2664
2024
Q4 		$169K Buy
9,523
+8,614
+948% +$191K ﹤0.01% 2681
2024
Q3 		$18.6K Buy
+909
New +$19.5K ﹤0.01% 3080

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Legal & General Group's RAPP Position: Q2 2026 in Review

Legal & General Group increased its Rapport Therapeutics (RAPP) stake by 31% in Q2 2026, buying an estimated $199K and bringing the position to 22,555 shares worth $940K. The position accounts for ﹤0.01% of the portfolio, ranked #2225.

Legal & General Group first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.01M in Q3 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Legal & General Group held 22,555 shares of Rapport Therapeutics worth $940K as of Q2 2026.
  • Legal & General Group bought 5,401 Rapport Therapeutics shares in Q2 2026, an estimated $199K.
  • Rapport Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2225 holding.
  • Legal & General Group first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Legal & General Group's Rapport Therapeutics position peaked at $1.01M in Q3 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.